Efficacy and safety of ferric carboxymaltose in Indian pregnant women with iron deficiency anemia

Mahesh Gupta; Aditya Gupta; Sachin Suryawanshi; Ketan Kulkarni

doi:10.18203/2320-1770.ijrcog20242499

Authors

Mahesh Gupta Department of Obstetrics and Gynecology, Pushpam Maternity Hospital and Sonography Centre and Matis Multispecialty Hospital, Ahmedabad, Gujarat, India https://orcid.org/0000-0001-7889-0048
Aditya Gupta Pushpam Maternity Hospital and Sonography Centre, Matis Multispecialty Hospital, Sunflower Multispeciality Hospital, Ahmedabad, Gujarat, India
Sachin Suryawanshi Department of Medical Services, Emcure Pharmaceuticals Ltd, Chandivali, Mumbai, Maharashtra, India
Ketan Kulkarni Department of Medical Services, Emcure Pharmaceuticals Ltd, Chandivali, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20242499

Keywords:

Ferric carboxymaltose, Pregnancy, Iron deficiency anemia

Abstract

Background: Ferric carboxymaltose (FCM) is a third-generation intravenous dextran-free, iron formulation that can be given in a single dose over a small duration. The study assessed hematological parameters before and after FCM administration in pregnant women for whole population and according to gestational age, severity of anemia and gravida status.

Methods: This was a single centre, prospective, observational, open label, clinical study at real life scenario with 4 weeks follow up. Thirty pregnant women with IDA and visiting to the Pushpam Maternity Hospital, Ahmedabad for antenatal care were enrolled for the study. I.V. FCM was administered as a single dose of 1000 mg. Change in the haemoglobin (Hb), ferritin, other hematological parameters at baseline and after 4 weeks of completion of parenteral iron therapy was noted.

Results: A significant increase in the haemoglobin (Hb) of 2.08 gm/dl and ferritin of 92.89 ng/ml was recorded at 4 weeks. There was a significant rise in Hb, ferritin, MCV, MCH, RBC count, MCHC as compared to the baseline in patients with moderate anemia. There was significant increase in Hb, hematocrit, ferritin and MCV as compared to baseline in primi and multigravida women and also in gestational age ≤ and >28 weeks. No adverse effects were observed throughout the duration of the study.

Conclusions: FCM infusion prior to delivery significantly increased hemoglobin levels and improved ferritin levels and other haematological parameters at 4 weeks in whole population and also in moderate anemia, primi, multigravida and gestational age ≤ and >28 weeks.

Metrics

Metrics Loading ...

References

John SE, Azizi K, Hancy A, Twin’omujuni A, Katana D, Shine J, et al. The prevalence and risk factors associated with Iron, vitamin B12 and folate deficiencies in pregnant women: a cross-sectional study in Mbeya, Tanzania. PloS Glob Public Health. 2023;3(4):e0001828.

National Family Health Survey, 2019-21, Compendium of Fact sheets, Key indicators, India and 14 States/UTs (Phase-II). Available from: https://mohfw.gov.in/sites/default/files/NFHS-5_Phase-II_0.pdf. Accessed on 11 June 2024.

Bharadwaj MK, Patrikar S, Singh Y. Comparative analysis of injection ferric carboxymaltose versus iron sucrose for treatment of iron-deficiency anemia in pregnancy: systematic review and meta-analysis. J South Asian Feder Obst Gynecol. 2023;15(5):629-36.

Charmila A, Natarajan S, Chitra TV, Pawar N, Kinjawadekar S, Firke Y, et al. Efficacy and safety of ferric carboxymaltose in the management of iron deficiency anemia: a multi-center real-world study from India. J Blood Med. 2022:303-13.

Ebea-Ugwuanyi PO, Vidyasagar S, Connor JR, Frazer DM, Knutson MD, Collins JF. Oral iron therapy: Current concepts and future prospects for improving efficacy and outcomes. Br J Hematol. 2024;00:1-15.

O’Toole F, Sheane R, Reynaud N, McAuliffe FM, Walsh JM. Screening and treatment of iron deficiency anemia in pregnancy: a review and appraisal of current international guidelines. Int J Gynecol Obstet. 2023;166(1):1-14.

Trivedi P, Chitra S, Natarajan S, Amin V, Sud S, Vyas P, et al. Ferric carboxymaltose in the management of iron deficiency anemia in pregnancy: a subgroup analysis of a multicenter real-world study involving 1191 pregnant women. Obstet Gynecol Int. 2022;2022:5759740.

Agarwal A, Wadhwani R, Badkur P, Agarwal J, Lodhi B, Fathima F. Effectiveness of single-dose ferric carboxymaltose in enhancing hemoglobin levels in pregnant women with moderate-to-severe iron-deficiency anemia. J South Asian Feder Obstet Gynaecol. 2023;15:424-7.

Eser A, Kyio NH. Efficacy and safety of intravenous ferric carboxymaltose in iron deficiency anemia; real-life data from Turkey, a single center experience. Med Sci. 2021;10(2):422-6.

LaVallee C, Cronin P, Bansal I, Kwong WJ, Boccia RV. Effectiveness of parenteral iron therapy in the real-world setting: a retrospective analysis. J Clin Haematol. 2020;1(1):103-6.

Shi H, Chen L, Wang Y, Sun M, Guo Y, Ma S, et al. Severity of anemia during pregnancy and adverse maternal and fetal outcomes. JAMA Netw Open. 2022;5(2):e2147046.

Rathod S, Samal SK, Mahapatra PC, Samal S. Ferric carboxymaltose: a revolution in the treatment of postpartum anemia in Indian women. Int J Appl Basic Med Res. 2015;5(1):25-30.

Agarwal A, Wadhwani R, Badkur P, Agarwal J, Lodhi B, Fathima F. Effectiveness of single-dose ferric carboxymaltose in enhancing hemoglobin levels in pregnant women with moderate-to-severe iron-deficiency anemia. J South Asian Feder Obstet Gynaecol. 2023;15:424-7.

Haniff J, Das A, Onn LT. Anaemia in pregnancy in Malaysia: a cross-sectional survey. Asia Pacific J Clin Nutr. 2007;16(3):527-36.